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Effect of a pharmacological intervention on quality of life in
patients with obsessive–compulsive disorder
Nienke H. Tenneya, Damiaan A.J.P. Denysa, Harold J.G.M. van Megena,
Gerrit Glasb and Herman G.M. Westenberga
Patients with obsessive–compulsive disorder (OCD) not
only suffer from obsessive–compulsive symptoms, but
also the disorder is associated with aberrant social
functioning and a diminished quality of life (QoL). Although
studies concerning the effect of treatment interventions on
symptoms are common, studies with regard to the effect of
treatment interventions on QoL are scarce. We examined
the effect of a pharmacological intervention on QoL in 150
patients with OCD. Furthermore, we studied whether two
different drugs, venlafaxine and paroxetine, differed in their
effect on QoL. Finally, we examined whether any found
improvement in QoL was related to improvement in
symptoms and/or the baseline self-directedness score,
which is one of the character dimensions of the psycho-
biological model of Cloninger. We demonstrated that QoL,
as assessed with the Lancashire Quality of Life Profile,
improved following pharmacological intervention, for which
paroxetine and venlafaxine appeared to be equally
effective. Furthermore, neither improvement in symptoms,
nor baseline self-directedness, was associated with the
improvement in QoL. Int Clin Psychopharmacol 18:29–33
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Introduction
Obsessive–compulsive disorder (OCD) is a chronic and
often disabling condition, afflicting approximately 0.7–
2.1% of the general population (Bebbington, 1998). OCD
patients not only suffer from symptoms, but the
condition also causes deficits in social functioning and
quality of life (QoL). Recent studies have shown that
patients with OCD show disabilities and poor QoL even
after amelioration of the OCD symptoms (Hollander et
al., 1996; Koran et al., 1996; Bystritsky et al., 2001).
Measures of QoL therefore seem to assess an important
aspect of OCD. Rather than a narrow symptom-focused
view, a more holistic view reflecting the complex and
broad impact that mental illness has on patients can be
obtained by using QoL instruments (Hansson et al.,
2001). Although a clear definition of QoL is lacking, the
patient’s subjective perceptions and feelings, concerning
basic life domains and life as a whole, are regarded as
central to QoL assessment (Barry et al., 1993).
Cross-sectional studies have indicated that QoL ratings in
patients with OCD are lower than in the general
population and comparable to those reported for
depressed patients and schizophrenic patients (Hollan-
der et al., 1996; Koran et al., 1996; Grabe et al., 2000; Bobes
et al., 2001). In order to be useful for treatment research,
measures of QoL should be sensitive to changes in
clinical and/or social conditions of patients. This would
require prospective longitudinal studies that evaluate the
same patients before and after interventions have taken
place, or when social conditions have changed. To the
best of our knowledge, only one prospective longitudinal
study with regard to QoL has been reported in OCD
patients. Bystritsky et al. (1999) examined the effect of
treatment, a combination of medication and behaviour
therapy, on a QoL measure in OCD. They found that
both QoL and obsessive–compulsive symptoms improved
following treatment, but changes in both domains were
unrelated.
Since Bystritsky et al. (1999) studied the effect of a
combination of behaviour therapy and medication, it
remains unclear whether improvement in QoL resulted
from the pharmacological intervention, the behaviour
therapy, or the combination of both. Due to the relatively
limited availability of behavioural treatment, at present,
most OCD patients are treated pharmacologically (Koran
et al., 2000). Therefore, it would be important to know
whether pharmacological treatment by itself will result in
improvement of QoL. Furthermore, a study in depression
has shown that different antidepressants can have
different effects on QoL (Souetre et al., 1996). In the
study by Bystritsky et al. (1999), no information was
available with regard to which pharmacological agents
were prescribed. In a recent study from our group, it was
shown that paroxetine and venlafaxine have the same
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effect on symptomatic improvement as measured with
the Yale–Brown Obsessive–Compulsive Scale (Y-BOCS)
(Denys, 2002). Whether the same holds for their effect
on QoL remains to be shown.
In a study of schizophrenic and schizoaffective patients,
on the relationship between QoL, symptoms and
personality dimensions, it was shown that the variance
of different measures of QoL was largely explained by
symptoms, and next to it, by one of the character
dimensions (i.e. self-directedness) from the psychobio-
logical model of Cloninger et al. (1993). Self-directedness
refers to the ability of an individual to control, regulate
and adapt behaviour to fit the situation in individually
chosen goals and values (Cloninger et al., 1993). The
relationship between personality and QoL has only been
studied cross-sectionally (Kentros et al., 1997; Hansson et
al., 2001). Hence, whether baseline personality ratings are
related to changes in QoL following treatment is
unknown.
The aims of this study were threefold. First, we wanted to
assess whether QoL is effected by pharmacological
treatment. The second aim was to study whether two
different drugs, venlafaxine and paroxetine, differed in
their effect on QoL. Third, we wanted to examine
whether treatment response and/or baseline self-directed-
ness scores were related to improvement in QoL.
Methods
Subjects
One hundred and fifty drug free patients with a primary
diagnosis of OCD according the DSM-IV (American
Psychiatric Association, 1994) participated in a double-
blind study comparing the efficacy of two antidepres-
sants, venlafaxine and paroxetine. The primary aim of this
study was to compare the efficacy of venlafaxine and
paroxetine, for which the results are published elsewhere
(Denys et al., 2002). The MINI International Neuropsy-
chiatric Interview (Sheehan et al., 1998) was used to
establish the diagnosis. Written informed consent was
obtained from all patients. Subjects were outpatients,
aged 18–70 years, with a minimum score of 16 on the Y-
BOCS. Patients with comorbid axis I conditions (major
depression; bipolar disorder; schizophrenia or any other
psychotic disorder; tic disorder; substance related dis-
order during the past 6 months) or a Hamilton
Depression Rating Scale (Hamilton, 1967) score higher
than 16 were excluded. Patients who used antidepres-
sants or neuroleptics 2 weeks before the screening visit or
fluoxetine 4 weeks before screening were also excluded.
Cognitive and/or behavioural treatment 3 months prior
the screening visit was also an exclusion criterion.
Patients taking psychotropic drugs, with the exception
of 30 mg of oxazepam or an equivalent dose of any other
benzodiazepine during the trial, were excluded from the
analysis.
Patients were randomly allocated to receive either
paroxetine (60 mg/day) or venlafaxine XR (300 mg/day)
fixed dose for 12 weeks. All measures were taken at
baseline and at the end of the 12-week treatment period,
except for the temperament and character inventory,
which was only administered at baseline.
Measures
Y-BOCS (Goodman et al., 1989)
The 10-item Y-BOCS was used to assess severity of
obsessive–compulsive symptoms. Higher scores (range
0–40) on this interview indicate more severe obsessive–
compulsive symptoms.
Hamilton Anxiety Rating Scale (HAS) (Hamilton, 1959)
The HAS was used as secondary symptom outcome
measures. It assesses severity of anxiety. Higher scores
indicate more severe symptomatology.
Temperament and Character Inventory (TCI) (Duijsens
et al., 1997)
The Dutch translation of the TCI, a 240-item ques-
tionnaire, was used to assess personality dimensions. It
allows for analyses of four temperament (i.e. harm
avoidance, novelty seeking, persistence and reward
dependence), and three character dimensions (i.e. self-
directedness, cooperativeness and self-transcendence).
We only used the self-directedness score in the present
study. While we decided to administer the TCI when the
trial was already running, it was only administered to the
last 75 patients participating in the trial.
The Lancashire Quality of Life Profile: extended Dutch
version (LqoLP) (Oliver et al., 1997; van Nieuwenhuizen
et al., 2001)
Quality of life was assessed with the LQoLP. The LQoLP
is a structured self-report interview to be administered by
trained interviewers. It assesses objective QoL and
subjective life satisfaction in six domains. An overall
subjective QoL score is obtainable, which comprises a
total score of subjective QoL on all domains. The
instrument also includes a global well being measure,
which is the sum of two questions concerning global well
being. It also contains a global self-reported QoL measure
where the subject rates the present life situation on a
worse-best possible scale. Subjective QoL ratings in the
domains, as well as global well being, are made on a
seven-point likert-type scale. Further subscales included
in the LQoLP, but not used in the present study, are an
affect balance scale, a self-esteem scale and a happiness
scale. The LQoLP has been used in a number of
international studies and has shown satisfactory results
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in reliability and validity tests (Oliver et al., 1997; van
Nieuwenhuizen et al., 2001).
Statistical analysis
Treatment results were analysed with a two (group:
venlafaxine versus paroxetine) by two (time: pre-treat-
ment versus post-treatment) design using multivariate
analyses of variance. In case of a multivariate significant
time effect, ANOVAs were performed for individual
outcome measures.
To examine whether improvement in QoL measures was
related to symptomatic improvement, patients were
divided into responders and non-responders on treat-
ment. Response was defined as a reduction of at least
35% on the Y-BOCS. Subsequently, treatment results
with regard to the QoL measures were analysed with a
two (group: responder versus non-responder) by two
(time) design. The same procedure was repeated with
high and low self-directedness as a between group factor.
Patients with a self-directedness score within (or above)
1 SD of the normal population were considered as
demonstrating high self-directedness. The sample with a
self-directedness score lower than 1 SD compared to the
normal population were considered as demonstrating low
self-directedness. Because the TCI was not directly
available at the start of the trial, the TCI analysis was
performed on a subset of the total sample.
Results
One hundred and one of the 150 patients who entered
the study were available for analysis. Forty-nine patients
were excluded from the analysis due to incomplete data.
Twenty-one patients did not complete the 12-week
treatment period and 28 patients were excluded because
of incomplete assessments. No differences in illness
duration, sex ratio, baseline QoL scores and symptom
severity existed between patients in the analyses and
patients who were excluded.
Of the 101 patients, 47 received paroxetine and 54
received venlafaxine. When the patient group was divided
into responders and non-responders to treatment, on the
basis of a reduction of at least 35% on the Y-BOCS, 49
subjects were rated as responders and 52 as non-
responders. Of the 69 patients of whom the TCI was
available, 31 subjects were classified as demonstrating low
self-directedness (scoring more than 1 SD under the
Dutch norms) and 38 subjects were classified as
demonstrating high self-directedness (scoring within or
above 1 SD of the Dutch norms).
Demographic and clinical characteristics of the patients
who entered the analyses are reported in Table 1. The
average score of 26 on the Y-BOCS in the present
population indicates a moderate severity of symptoms
(Goodman and Price, 1992). Most patients had been
treated previously for OCD, 57% had received drug
treatment, while 40% of the patients had previously
received behaviour therapy.
As shown in Table 2, the paroxetine and venlafaxine
group improved following treatment on all measures.
Symptoms decreased and QoL increased. Repeated
measures analysis revealed a main effect for time
(F ¼ 18.33, d.f. ¼ 1, Po 0.000), but no time by drug
interaction (F ¼ 1.75, d.f. ¼ 1, P ¼ 0.189). ANOVAs for
individual outcome measures revealed a main effect for
time and no interaction between time by drug for the
symptom measures (i.e. the Y-BOCS and the HAS),
as well as the QoL measures (i.e. global subjective
well being, overall QoL and general subjective QoL)
(Table 3).
Repeated analysis of variance for the QoL measures with
time as within factor and responder status as between
factor, revealed a main effect for time (F ¼ 8.06, d.f. ¼ 1,
P ¼ 0.005) and no interaction between time by respon-
der status (F ¼ 0.015, d.f. ¼ 1, P ¼ 0.901). The same
analysis was repeated, but with low versus high self-
directedness as between factor, in a subset of 69 patients.
Again a main effect for time was found (F ¼ 4.69,
Table 2 Mean scores for Y-BOCS, HAS, global subjective well
being, overall subjective well being, and global subjective quality of
life pre-and post treatment for the paroxetine and venlafaxine
group
Pre-treatment SE Post-treatment SE
Paroxetine
Y-BOCS 24.8 0.74 16.2 1.1
HAS 10.9 0.96 5.7 0.64
Global subjective well-being 9.6 0.33 8.1 0.33
Overall subjective quality of life 32.8 0.57 31.6 0.62
Global subjective quality of life 90.6 13.95 52.2 3.57
Venlafaxine
Y-BOCS 26.5 0.67 18.2 0.99
HAS 11.3 0.88 7.1 0.58
Global subjective well-being 8.7 0.30 7.4 0.29
Overall subjective quality of life 31.0 0.53 29.8 0.57
Global subjective quality of life 59.9 12.76 46.0 3.26
Y-BOCS, Yale–Brown Obsessive–Compulsive Scale; HAS, Hamilton Anxiety
Rating Scale.
Table 1 Characteristics of the sample
n %
Age, mean (SD) 36 (12)
Sex
Woman 65 63.7
Man 37 36.3
Y-BOCS, mean (SD) 26 (5)
HAS, mean (SD) 11 (6)
Treated earlier for OCD 82 80.4
Illness duration, mean
(SD)
16 (11)
Y-BOCS, Yale–Brown Obsessive–Compulsive Scale; HAS, Hamilton Anxiety
Rating Scale; OCD, obsessive–compulsive disorder.
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d.f. ¼ 1, P ¼ 0.034) but no interaction between time by
low versus high self-directedness (F ¼ 0.346, d.f. ¼ 1,
P ¼ 0.558).
Discussion
The aim of the present study was to examine whether
QoL was affected by pharmacological treatment. The
results indicate that all three QoL ratings were improved
after the 12-week treatment period. Furthermore, the
class of drug prescribed, venlafaxine or paroxetine, did
not appear to have a differential effect. In other words,
with regard to QoL improvement, venlafaxine and
paroxetine, are equally effective. This is in line with
the effects of venlafaxine and paroxetine on symptomatic
improvement (Denys, 2002). In addition, it was found
that responders and non-responders, as defined with a
reduction of 35% on the Y-BOCS, did not differ with
regard to improvement of QoL. Finally, baseline self-
directedness scores were not related to QoL improve-
ment. It was found that high versus low self-directedness
did not differentiate in QoL improvement.
As mentioned in the introduction, in order to be useful in
treatment research, QoL measures should be sensitive for
changes. This appears to be the case for the Lancashire
Quality of Life Profile (van Nieuwenhuizen et al., 2001),
which was used in this study. All three scales (global
subjective well being, overall subjective QoL and global
subjective QoL) of the Lancashire Quality of Life Profile
showed statistically significant changes. However,
although the changes were statistically significant, with
regard to the scales global subjective well being and
overall subjective QoL, the absolute changes were small.
Whether this statistically significant difference is also
clinically meaningful requires further clarification.
Only one study in OCD reported on the effect of
treatment on QoL (Bystritsky et al., 1999). It was found
that QoL improved following treatment consisting of a
combination of pharmacological and behaviour therapy.
To the best of our knowledge, this is the first study in
OCD showing that QoL improves following pharmacolo-
gical intervention. This is of importance because,
currently, many OCD patients are treated pharmacologi-
cally. In depression, it was already shown that pharmaco-
logical treatment can result in improvement in QoL
(Souetre et al., 1996; Aberg-Wistedt et al., 2000; Kroenke et
al., 2001). Thus, pharmacological interventions can lift a
patient’s QoL, at least in OCD and depression.
In addition, improvement in QoL seems to occur
independently of improvement in obsessive–compulsive
symptoms. Responders and non-responders on treatment
did not differ in their improvement in QoL. This seems
to imply that changes in symptom severity have no
bearing on improvement of QoL, and corroborates the
findings of Bystritsky et al. (1999), who demonstrated
only marginal relations between changes in symptoms and
changes in QoL. Therefore, the effect of treatment on
QoL does not appear to result from the effect of
treatment on symptoms.
Cross-sectional studies have shown that personality
dimensions may affect how patients experience their
QoL (Kentros et al., 1997; Hansson et al., 2001). It was
previously questioned whether changes in QoL would be
related to these personality dimensions. Hansson et al.
(2001) showed that especially self-directedness, one of
the character dimensions of the psychobiological model of
Cloninger et al. (1993), was able to explain most of the
variance compared to the other personality dimensions in
the QoL of schizophrenic patients (i.e. high self-
directedness was associated with a better QoL). Conse-
quently, we used this dimension of the psychobiological
model (Cloninger et al., 1993), and divided patients into
high and low self-directedness. In agreement with the
findings of Hansson et al. (2001), we expected that
patients scoring high on self-directedness would show the
greatest improvement in QoL. Contrary to our expecta-
tions, this was not the case. A possible explanation for this
finding might be that these patients already have a high
QoL and therefore have a smaller margin in which they
can improve. Furthermore, the effect of treatment on
self-directedness in OCD has not been investigated
previously. However, in generalized anxiety disorder and
major depressive disorder, it was found that self-
directedness increased following treatment (Allgulander
et al., 1998; Richter et al., 2000). If this is also true for
OCD, changes in QoL would be expected to be related to
changes in self-directedness following treatment, instead
of to the baseline self-directedness score that we used.
Because improvement in QoL was unrelated to sympto-
matic improvement and the baseline self-directedness
Table 3 ANOVAs for the Y-BOCS, HAS, global subjective well being,
overall subjective well being, and global subjective quality of life
with time as within factor and drug as between factor
Measures F d.f. P
Y-BOCS
Time 176.22 1, 99 o0.000
Time  drug 0.527 1, 99 0.873
HAS
Time 56.78 1, 99 o0.000
Time  drug 0.716 1, 99 0.399
Global subjective well-being
Time 41.55 1, 99 o0.000
Time  drug 0.092 1, 99 0.762
Overall subjective quality of life
Time 17.99 1, 99 o0.000
Time  drug 0.036 1, 99 0.85
Global subjective quality of life
Time 7.49 1, 99 0.007
Time  drug 1.66 1, 99 0.200
Y-BOCS, Yale–Brown Obsessive–Compulsive Scale; HAS, Hamilton Anxiety
Rating Scale.
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score, the questions emerges of what is being measured
with the change in QoL. It could be assumed that the
change in QoL is the result of a non-specific treatment
effect. Possibly, patients undergoing treatment, irrespec-
tive of the effect of that treatment, rate their QoL higher
than untreated patients. The hope on change, or the
experience of undertaken action to improve the present
situation may be responsible for this effect. Conse-
quently, this raises the question of how long the effect
lasts. Does it sustain in all patients, or only in those
patients who really have improved as a result of treatment
and ultimately deteriorate in patients who have not
experienced any improvement. In future studies, QoL
should be measured over a larger time frame following
treatment in order to address this question.
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